

[Leu31,Pro34]-Neuropeptide Y(human, rat, mouse) TFA

| | | |
|-----------------------------|---|---|
| Cat. No.: | HY-P1323A | |
| Molecular Formula: | C ₁₉₁ H ₂₈₅ F ₃ N ₅₄ O ₅₈ S | |
| Molecular Weight: | 4354.76 | Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Ty |
| Sequence: | Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Ty r-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH ₂ | Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH ₂ (TFA salt) |
| Sequence Shortening: | YPSKPDNPGEDAPAEDMARYSALRHYINLLTRPRY-NH ₂ | |
| Target: | Neuropeptide Y Receptor | |
| Pathway: | GPCR/G Protein; Neuronal Signaling | |
| Storage: | Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year | |
| | * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | |

SOLVENT & SOLUBILITY

| | | | | | | |
|---|---|--------------------------|-----------|-----------|-----------|-------|
| In Vitro | H ₂ O : 50 mg/mL (11.48 mM; Need ultrasonic) | | | | | |
| | | Solvent Concentration | Mass | 1 mg | 5 mg | 10 mg |
| | Preparing Stock Solutions | 1 mM | 0.2296 mL | 1.1482 mL | 2.2963 mL | |
| | | 5 mM | 0.0459 mL | 0.2296 mL | 0.4593 mL | |
| | | 10 mM | 0.0230 mL | 0.1148 mL | 0.2296 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | | |

BIOLOGICAL ACTIVITY

| | | | |
|-------------------------------------|--|---------------------------|---------------------------|
| Description | [Leu31,Pro34]-Neuropeptide Y(human, rat) TFA is a specific neuropeptide Y ₁ receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human, rat) TFA also activates Y ₄ , Y ₅ . [Leu31,Pro34]-Neuropeptide Y(human, rat) TFA can increase blood pressure in anesthetized rats and increases food intake ^{[1][2]} . | | |
| IC₅₀ & Target | NPY ₁ receptor | NPY ₄ receptor | NPY ₅ receptor |
| In Vitro | [Leu31,Pro34]-Neuropeptide Y(human, rat) TFA has K _i values of 0.39 nM, 0.499 nM, 0.31 nM for Y ₁ , Y ₄ , Y ₅ in HEK cell lines. [Leu31,Pro34]-Neuropeptide Y(human, rat) TFA has a K _i of >1000 for Y ₂ in HEK cell lines ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | |
| In Vivo | [Leu31,Pro34]-Neuropeptide Y(human, rat) TFA (30 pmol; microinjected into paraventricular nucleus) increases food intake in the rats (350±400 g) ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | |

CUSTOMER VALIDATION

- J Headache Pain. 2023 May 25;24(1):61.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. K McCrea, et al. 2-36[K4,RYSA(19-23)]PP a novel Y_5 -receptor preferring ligand with strong stimulatory effect on food intake. Regul Pept. 2000 Feb 8;87(1-3):47-58.
- [2]. J Fuhlendorff, et al. [Leu31, Pro34]neuropeptide Y: a specific Y_1 receptor agonist. Proc Natl Acad Sci U S A. 1990 Jan;87(1):182-6.
- [3]. A Kask, et al. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y_1 -selective antagonist BIBP3226. Br J Pharmacol. 1998 Aug;124(7):1507-15.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA